All In Biotech

Drug Trial Radar · NCT06801509

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Recombinant Herpes Zoster Vaccine

A Randomized, Double-blind, Controlled Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of the Recombinant Herpes Zoster Vaccine in Healthy Adults

Last checked: Nov 19, 2026Latest source record: Jan 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 540 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

540

Planned (sponsor's estimate)

Start

Feb 15, 2025

Primary completion

Nov 10, 2025

Study completion Oct 10, 2027

Sponsor

Lead sponsor
Sinocelltech Ltd.Industry
Sponsor type
Industry
First posted
Jan 30, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 40 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purposes of the study are to evaluate the Safety, Tolerability, and Immunogenicity of different dose levels of recombinant herpes zoster vaccine with 2 doses 60 days apart in healthy subjects aged 40 years and older.

Conditions

  • Herpes Zoster

Interventions

  • Recombinant Herpes Zoster Vaccine (SCTV04C) Low-DoseBiological

    Route of vaccination: intramuscular injection into the lateral deltoid of the upper arm; Immunization procedure: 2 doses, 60 days apart;

  • Recombinant Herpes Zoster Vaccine (SCTV04C) High-DoseBiological

    Route of vaccination: intramuscular injection into the lateral deltoid of the upper arm; Immunization procedure: 2 doses, 60 days apart;

  • Placebo control: SalineBiological

    The placebo in this study is 0.9% sodium chloride (normal saline) injection; Immunization procedure: 2 doses, 60 days apart;

  • Shingrix®Biological

    Route of vaccination: intramuscular injection into the lateral deltoid of the upper arm; Dosage of vaccination: 50 μg; Immunization procedure: 2 doses, 60 days apart

  • Ganwei®Biological

    Route of vaccination: subcutaneous injection into the lateral deltoid of the upper arm; Dosage of vaccination: 0.5 mL; Immunization procedure: saline will be administered at Day 0, and Ganwei® will be administered at Day 60;

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. phase 1: Incidence and intensity of solicited adverse events (AEs)Time frame: within 14 days after each vaccination
  2. phase 1: Incidence and intensity of unsolicited AEsTime frame: within 30 days after each vaccination
  3. phase 2: Geometric mean concentration (GMC) and seroconversion rate of antigen-specific antibodyTime frame: at 30 days after full vaccination

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Dazhu CDC

    Dazhou, Sichuan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.